Clinical trials: Ascites
Ovarian Cancer, Ovarian Neoplasms
AZD9150, a STAT3 Antisense Oligonucleotide, in People With Malignant Ascites
Background: Some people with gastrointestinal or ovarian cancer also have ascites. That is free fluid built up in the abdomen. Researchers want to see if a new drug can affect some of the immune cells in the ascites.
- Conditions
- Ovarian Cancer, Ovarian Neoplasms, Ascites, Gastrointestinal Cancer
- Trial name
- NCT02417753
- Testing
- AZD9150
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Octreotide in Treating Patients With Cancer-Related Malignant Ascites
RATIONALE: Octreotide may be an effective treatment for malignant ascites. It is not yet known whether octreotide is more effective than a placebo in treating malignant ascites.
- Trial name
- NCT00182754
- Testing
- octreotide acetate
- Where
- 122 sites in United States
- Volunteers
- 33 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Decompensated Cirrhosis and Ascites
Effects of Long-Term Administration of Human Albumin in Participants With Decompensated Cirrhosis and Ascites
This is a phase 3, multicenter, randomized, controlled, parallel-group, and open-label clinical study to evaluate the efficacy of standard medical treatment (SMT) + Albutein 20% administration versus SMT alone in participants…
- Trial name
- PRECIOSA (NCT03451292)
- Testing
- Albutein 20%, SMT
- Where
- 66 sites in United States, Belgium and 12 more
- Volunteers
- 410 people
- Sponsor
- Grifols Therapeutics LLC
Acute-On-Chronic Liver Failure, Ascites
Efficacy, Safety and Tolerability of VS-01 in Adult Patients With Acute-on-Chronic Liver Failure and Ascites (UNVEIL-IT)®
A Phase 2, multi-center, randomized, controlled, open-label study to evaluate the effects of the intraperitoneal, liposomal formulation VS-01 in patients with an acute episode of hepatic and/or extrahepatic organ dysfunctions and…
- Trial name
- NCT05900050
- Testing
- VS-01 on top of SOC, SOC (Control Group)
- Where
- 26 sites in United States, Belgium and 5 more
- Volunteers
- 15 people
- Sponsor
- Genfit
Cirrhosis, Liquid of Ascites
Evaluation of the Strip PeriScreen for the Fast Diagnosis of the Spontaneous Infection of the Liquid of Ascites During the Cirrhosis
The forecast of the spontaneous infection of the liquid of ascites (ISLA) at the cirrhotic patient is still burdened by a heavy mortality. The fast diagnosis of the ISLA is thus an essential stake to improve the forecast.
- Conditions
- Cirrhosis, Liquid of Ascites, Infection
- Trial name
- Per-DRISLA (NCT02085915)
- Testing
- strip Peri Screen
- Where
- 22 sites in Belgium, France
- Volunteers
- 649 people
- Sponsor
- Centre Hospitalier Departemental Vendee
Malignant Ascites
Study of the Trifunctional Antibody Catumaxomab to Treat Recurrent Symptomatic Malignant Ascites
The purpose of this study is to determine whether the investigational drug catumaxomab is a safe and effective treatment for recurrent symptomatic malignant ascites.
- Trial name
- NCT00326885
- Testing
- catumaxomab
- Where
- 18 sites in United States
- Volunteers
- 32 people
- Sponsor
- Neovii Biotech
Gynecologic Cancer, Gastrointestinal Cancer
BOLSTER: Building Out Lifelines for Safety, Trust, Empowerment and Renewal
This research study is evaluating a new intervention, BOLSTER, which was designed to provide more support for patients with gynecologic and gastrointestinal cancers and their caregivers after a hospitalization.
- Trial name
- NCT03367247
- Testing
- BOLSTER, Enhanced Discharge Planning (EDP)
- Where
- United States
- Volunteers
- 121 people
- Sponsor
- Dana-Farber Cancer Institute
Ovarian Neoplasms, Ascites
Study of the Effect of Intravenous AVE0005 (VEGF Trap) in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites
This study was designed to characterize the effect of aflibercept in participants with advanced chemoresistant ovarian cancer. Primary objective: Compare the effect of aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)…
- Trial name
- NCT00327444
- Testing
- aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)
- Where
- 9 sites in United States, Austria and 7 more
- Volunteers
- 58 people
- Sponsor
- Sanofi
Cirrhosis
A Study to Investigate Pharmacodynamics and Pharmacokinetics of OPC-41061 in Patients With Hepatic Edema
OPC-41061 at 3.75 mg/day or 7.5 mg/day will be orally administered once daily for 7 days to cirrhosis patients with ascites despite having received treatment with conventional diuretics and pharmacodynamics, pharmacokinetics…
- Trial name
- NCT01114828
- Testing
- OPC-41061
- Where
- Japan
- Volunteers
- 40 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Refractory Ovarian Cancer With Recurrent Symptomatic Malignant Ascites
Phase 1/2a Two-Arm Dose-Escalation Study of BAX69 in Subjects With Malignant Ascites of Ovarian Cancer
The purpose of this study is to evaluate the safety and tolerability of BAX69 monotherapy given either as intraperitoneal (IP) infusion (Single-Route Arm); or as IP infusion after intravenous (IV) infusion (IV+IP) (Double-Route…
- Trial name
- NCT02540356
- Testing
- BAX69 Single-Route Arm, BAX69 Double-Route Arm
- Where
- 6 sites in United States
- Volunteers
- 2 people
- Sponsor
- Baxalta now part of Shire
Liver Cirrhosis, Portal Hypertension
Early TIPS for Ascites Study
The purpose of this study is to demonstrate that TIPS with the GORE® VIATORR® TIPS Endoprosthesis improves transplant-free survival compared to LVP alone in patients who have cirrhosis of the liver with portal hypertension and…
- Conditions
- Liver Cirrhosis, Portal Hypertension, Ascites
- Trial name
- NCT01236339
- Testing
- TIPS procedure with the GORE® VIATORR® TIPS Endoprosthesis, LVP, TIPS procedure with the GORE® VIATORR® TIPS Endoprosthesis for subjects who failed LVP and crossed over to TIPS per protocol
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- W.L.Gore & Associates
Ascites
Trial of Sunitinib for Refractory Malignant Ascites
The study is to see whether treatment with Sunitinib decreases the accumulation of ascites in patients with refractory malignant ascites.
- Trial name
- NCT00796861
- Testing
- Sunitinib
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Milton S. Hershey Medical Center
Ascites, Cirrhosis
Vasoconstrictors as Alternatives to Albumin After Large-Volume Paracentesis (LVP) in Cirrhosis
This clinical trial compares a combination of two drugs that constrict blood vessels (Octreotide LAR and Midodrine) to albumin after large volume paracentesis. Subjects have cirrhosis and ascites.
- Trial name
- NCT00108355
- Testing
- Albumin, Midodrine, Octreotide LAR
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- US Department of Veterans Affairs
Ascites, Cirrhosis
Improving Performance of Paracentesis in Medical Residency Training
The investigators hypothesize that there is significant variability in management of patients with ascites despite guidelines provided by the American Association for the Study of Liver Diseases, the professional organization…
- Trial name
- NCT01403987
- Testing
- Residency Program Teaching, Lecture, Pocket Card Reference
- Where
- United States
- Volunteers
- 136 people
- Sponsor
- Boston Medical Center
Malignant Ascites
An Early Safety and Efficacy Study of Ascites Management: Standard Paracentesis or Early Intervention With Pleurx Catheters in Patients With Malignant Ascites
The purpose of this study is to assess in a controlled prospective setting, the safety of the use of Pleurx catheters and standard therapeutic paracentesis in patients with malignant ascites.
- Trial name
- NCT01077063
- Testing
- paracentesis, Pleurx catheter
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Portal Hypertension, Liver Diseases
Achieving Portal Access With Scorpion Post-Approval Study (APASS)
Creation of the parenchymal tract between the portal vein and the hepatic vein is the most difficult and time consuming step in a TIPS procedure.
- Conditions
- Portal Hypertension, Liver Diseases, Ascites Hepatic, Hydrothorax
- Trial name
- NCT05765253
- Testing
- Scorpion Portal Vein Access Kit, Cook Transjugular Liver Access Set, Transjugular Intrahepatic Portosystemic Shunt (TIPS)
- Where
- 3 sites in United States
- Volunteers
- 3 people
- Sponsor
- Argon Medical Devices
Peritoneal Neoplasms, Ascites
Local mEHT + TCM Versus Intraperitoneal Chemoinfusion in Treatment of Malignant Ascites: Phase II RCT
This trial studies efficacy and safety of combination of modulated electro-hyperthermia (mEHT) with Traditional Chinese Medicine (TCM) in treatment of peritoneal carcinomatosis with malignant ascites versus standard chemoinfusion…
- Conditions
- Peritoneal Neoplasms, Ascites, Yang Deficiency, Yin Deficiency
- Trial name
- OTMA-RII (NCT02638051)
- Testing
- Modulated Electro-Hyperthermia (mEHT), TCM Herbal Decoction (Shi Pi), IPCI (CDDP+5FU)
- Where
- China
- Volunteers
- 260 people
- Sponsor
- Galenic Research Institute Ltd
Cirrhosis, Ascites
The BRAINFOOD Trial to Prevent Recurrent Hepatic Encephalopathy.
This study is being completed for patients with cirrhosis, including patients with a prior history of hepatic encephalopathy (HE) to evaluate the feasibility and benefits of medically-tailored meals as an intervention.
- Conditions
- Cirrhosis, Ascites, Liver Diseases, Frailty
- Trial name
- NCT04675775
- Testing
- Medically-tailored meals (MTM), Protein supplements, Nutrition education handout
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Michigan
Cirrhosis
A Trial to Investigate the Efficacy of OPC-41061 Administered at a Dose of 7.5 mg in Patients With Hepatic Edema
OPC-41061 at 7.5 mg/day or placebo will be orally administered once daily for 7 days to cirrhosis patients with ascites despite having received treatment with conventional diuretics and the change in body weight from baseline at…
- Trial name
- NCT01050530
- Testing
- OPC-41061
- Where
- 8 sites in Japan
- Volunteers
- 162 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Ascites Hepatic
A Study of OsrHSA in Adult Healthy Male and Female Volunteers
A Phase 1 randomized, double blinded, placebo-controlled single dose escalation study of OsrHSA in adult healthy male and female volunteers
- Trial name
- NCT04384523
- Testing
- OsrHSA 20 mg/kg IV, OsrHSA 40 mg/kg IV, OsrHSA 80 mg/kg IV
- Where
- United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Healthgen Biotechnology Corp.